Log in
Enquire now
‌

US Patent 11771776 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Patent 11771776 was granted and assigned to Dyne Therapeutics on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Dyne Therapeutics
Dyne Therapeutics
Current Assignee
Dyne Therapeutics
Dyne Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11771776
Patent Inventor Names
Mohammed T. Qatanani
Cody A. Desjardins
John Najim
Timothy Weeden
Brendan Quinn
Romesh R. Subramanian
Date of Patent
October 3, 2023
Patent Application Number
17811370
Date Filed
July 8, 2022
Patent Citations
‌
US Patent 8084601 Oligomers
‌
US Patent 8232384 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
‌
US Patent 8324371 Oligomers
‌
US Patent 8361979 Means and method for inducing exon-skipping
‌
US Patent 8455636 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
‌
US Patent 8486907 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
‌
US Patent 8524880 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
‌
US Patent 8759507 Modulation of exon recognition in pre-mRNA by interfering RNA structure
...
Patent Citations Received
‌
US Patent 11986537 Muscle targeting complexes and uses thereof for treating dystrophinopathies
0
‌
US Patent 12005124 Muscle targeting complexes and uses thereof for treating dystrophinopathies
0
‌
US Patent 12012460 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
0
‌
US Patent 12018087 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
0
‌
US Patent 12128109 Muscle targeting complexes and formulations for treating dystrophinopathies
0
‌
US Patent 12102687 Muscle targeting complexes and uses thereof for treating myotonic dystrophy
0
‌
US Patent 11911484 Muscle targeting complexes and uses thereof for treating myotonic dystrophy
0
‌
US Patent 11931421 Muscle targeting complexes and formulations for treating myotonic dystrophy
0
...
Patent Primary Examiner
‌
Sheela J. Huff
CPC Code
‌
A61K 47/6849
‌
A61P 21/00
‌
A61K 47/6807
‌
A61K 47/6889
Patent abstract

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11771776 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.